Canadian Association for the Study of the Liver’s Post

Uncover the power of four liver steatosis indices! 🌟 Our latest article explores their efficacy in predicting Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) using quantitative computed tomography. Are you keen to delve into the insights? Simply scan the QR code below to read on and stay ahead in understanding liver health. Let's dive into the fascinating world of hepatology together! 🔬📚 #LiverHealth #MAFLD #HepaticSteatosis #MedicalResearch https://lnkd.in/g4Njza9r

📢 NEW CME VIDEO! Diagnosis and staging of MASLD/MASH. Metabolic dysfunction associated steatotic liver disease (#MASLD), previously known as non-alcoholic fatty liver disease (#NAFLD) is an increasingly common condition affecting 25% of the global population, and is especially prevalent in those with central #obesity and/or type 2 #diabetes. Can you identify the routine and symptom-directed tests and stratify patient risk? Spend 7-mins with Prof. Sven Francque as he illustrates the diagnostic pathway for patients with MASLD and discusses the recommended approach to staging of disease progression. PLUS! complete the 3-min evaluation and earn 0.25 FREE CME credits! 👉 https://lnkd.in/dPtnCf-e #MASH #MASLD #NASH #NAFLD #liverdisease #obesity #diabetes #T2D #steatosis #steatohepatitis #cirrhosis #WorldLiverDay EASL | The Home of Hepatology

No more NAFLD! #Steatotic #Liver Disease is the overarching term; #NAFLD is now #MASLD. Could you spot MASLD? Now affecting over a quarter of the global population, don't miss this 7-min CME video on testing and diagnostic pathways. 👉 https://lnkd.in/d2thdMXy #nurse #pcp #primarycare #physician #registerednurse #worldliverday

📢 NEW CME VIDEO! Diagnosis and staging of MASLD/MASH. Metabolic dysfunction associated steatotic liver disease (#MASLD), previously known as non-alcoholic fatty liver disease (#NAFLD) is an increasingly common condition affecting 25% of the global population, and is especially prevalent in those with central #obesity and/or type 2 #diabetes. Can you identify the routine and symptom-directed tests and stratify patient risk? Spend 7-mins with Prof. Sven Francque as he illustrates the diagnostic pathway for patients with MASLD and discusses the recommended approach to staging of disease progression. PLUS! complete the 3-min evaluation and earn 0.25 FREE CME credits! https://lnkd.in/dPtnCf-e #MASH #MASLD #NASH #NAFLD #liverdisease #obesity #diabetes #T2D #steatosis #steatohepatitis #cirrhosis #WorldLiverDay EASL | The Home of Hepatology

Data recently published in The Lancet Gastroenterology & Hepatology demonstrates efficacy and safety of our investigative therapy in moderately to severely active ulcerative colitis (UC) among patients living with or without prior inadequate response/intolerance to advanced therapy through the induction period of 12 weeks. Additional data published by the American Gastroenterological Association (AGA)’s Gastroenterology journal supports the efficacy and safety of our investigative therapy through up to 48 weeks in patients living with Crohn’s disease (CD). These insights further reinforce our commitment to people living with UC and CD, as we work toward a future where immune-mediated diseases are a thing of the past. Learn more about our ongoing research in gastroenterology: https://bit.ly/3mZDLf8 #JNJImmunology #Gastroenterology #UlcerativeColitis #CrohnsDisease

After an announcement on behalf of multinational liver societies last year, non-alcoholic fatty liver disease (NAFLD) is diagnosed and recognized as metabolic dysfunction-associated steatotic liver disease (MASLD). Experts from 50 countries convened in a two-year process that resulted in new categories and terminologies for multiple liver diseases and conditions, which they argued were more accurate and could help the field of liver study get specific about its patient populations. With researchers, medical journals, regulatory bodies and advocacy groups already widely adapting the new terminology for their own uses, STAT notes that the true challenge of the transition will now be educating patients and providers about the names.    While there are no treatments approved for metabolic dysfunction-associated steatohepatitis (MASH; formerly non-alcoholic steatohepatitis) or MASLD, a strong focus on research continues with two new investments from major industry players announced this week alone. #MASH #MASLD #LiverDisease

NEW BLOG: MASLD: The Rebrand You've Never Heard Of When non-alcoholic fatty liver disease changed its name last year, did any one notice? Now termed MASLD, or metabolic dyfunction-associated steatotic liver disease, the rebrand has failed to trigger the wave recognition this condition deserves. In our latest NB blog, Neal Tucker discusses why non-alcoholic fatty liver disease (NAFLD) has changed and the clinical implications, as well as new research examining how existing medications could be utilised to prevent the associated complications in the liver and beyond. Click on the link to read the full article. #PrimaryCare #Hepatology #LiverDisease #HotTopics

Check out this 10 minute video on the new name for Fatty Liver Disease. Did you know this is a disease on the rise? Find out more with Rotonya Carr, board member from American Liver Foundation and one of my favorite doctors. #fattyliverdisease #MASLD #MASH #liverhealth #liverdisease #ALF #LiverFoundation #engagement #awareness

📢 Here is a must-read, hepatolovers! 📢 "Managing Pruritus in Chronic Liver Disease: An In-depth Narrative Review" just recently published in Clinical Liver Disease. 🔍 This review dives deep into the challenges and strategies for managing pruritus, a common and often debilitating symptom in patients with chronic liver disease. 🧐The authors explore current treatment options, underlying mechanisms, and future directions for research and clinical practice. 👉 If you're interested in hepatology, this is a must-read! Enhance your understanding and stay updated with the latest insights in the field. #Hepatology #ChronicLiverDisease #Pruritus #LiverHealth #ClinicalResearch #MedicalEducation #AnnalsOfHepatology #ClinicalLiverDisease